Skip to main content

Geisinger welcomes expert consensus statement published in JACC

DANVILLE, Pa. – High cholesterol can be the result of poor diet and exercise, but it can also be an inherited genetic disorder. In its genetic form, it is known as familial hypercholesterolemia (FH) and it’s an often-invisible killer. FH causes high low-density lipoprotein (LDL) cholesterol, sometimes referred to as ‘bad cholesterol,’ to accumulate from an early age.

It can begin to cause cardiovascular damage in children and, overall, individuals with FH have a six- to 20-times increased lifetime risk of heart disease.

Geisinger’s own studies from the MyCode Community Health Initiative have shown that FH is both underdiagnosed and undertreated in our own community. 

The FH Foundation convened an international expert panel that included Geisinger’s director of cardiovascular genomic counseling, Amy Sturm, M.S., CGC, which issued a new recommendation on testing for FH based on their review.

Ms. Sturm and the international panel of 30 cardiovascular, lipid, genetics and advocacy experts recommended that genetic testing be offered to diagnose individuals with FH, and importantly their first-degree relatives as well. Parents, children and siblings of an FH patient have a 50% chance of having the disease. FH genetic mutations lead to heart disease and stroke risk during the prime of life and affect an estimated 30 million people worldwide, 90% of whom are undiagnosed.

The consensus statement of the expert panel is that all patients with a family history of early heart disease and who have elevated LDL cholesterol should be offered genetic testing to see if they have FH, the inherited form of the disease. The full statement was published online July 30 in the Journal of the American College of Cardiology

As the nation’s only healthcare system conducting large-scale, genomic population health screening, Geisinger welcomes the recommendations today from the expert panel.

“Diagnosing and treating FH in childhood reduces the risk of early heart disease by about 80 percent, which is why it’s so important to find families with FH, and especially children who have this invisible, life-threatening genetic disorder,” said Sturm. “In addition, understanding the exact genetic mutation can better inform the initiation and treatment of FH with more intense lipid-lowering therapies and ultimately improve outcomes.”

David. H. Ledbetter, Ph.D., Geisinger executive vice president and chief scientific officer, was also a member of the expert panel and a co-author of the study. According to Ledbetter, “More than 100 Geisinger patients have already been identified with FH genomic variants as a result of the MyCode Genomic Screening and Counseling program and that number will rise as the program continues. Additionally, more will be found with the implementation of the clinical DNA sequencing program at Geisinger. The recommendation from this FH Foundation-sponsored expert panel is an important step forward in identifying and treating this disorder and making genetic testing a standard of care for this life-threatening illness.”


About Geisinger
One of the nation’s most innovative health services organizations, Geisinger serves more than 1.5 million patients in Pennsylvania and New Jersey. The system includes 13 hospital campuses, a nearly 600,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine. Geisinger is known for its focus on caring and innovative programs including the ProvenCare® best-practice approach to maximize quality, safety and value; ProvenHealth Navigator® advanced medical home; Springboard Health® population health program to improve the health of an entire community; ProvenExperience™ to provide refunds to patients unhappy with their care experience; and Geisinger’s MyCode® Community Health Initiative, one of the largest healthcare system-based precision health projects in the world. With more than 245,000 volunteer participants enrolled and over 145,000 sequenced, MyCode is conducting extensive research and returning potentially life-saving results to participants. A physician-led organization, with approximately 32,000 employees and more than 1,800 employed physicians, Geisinger leverages an estimated $12.7 billion positive annual impact on the Pennsylvania and New Jersey economies. Repeatedly recognized nationally for integration, quality and service, Geisinger has a long-standing commitment to patient care, medical education, research and community service. For more information, visit, or connect with us on Facebook, Instagram, LinkedIn and Twitter.